With an “out-of-the-box” approach, mainly in the pre-clinical research field, we could assume that the finding of ER-low positivity might not preclude ET but rather guide a strategy aiming to reverse this process and re-sensitize the tumor to ET [64]. This evidence concerns the gene ESR1 and neoplasm.